Scri Development Innovations, Llc

This study is testing whether combining two drugs, tucatinib and Doxil, is safe and effective for treating HER2+ breast cancer that has spread or returned after prior treatment. It will involve about 36 patients who have already tried at least one other HER2-targeted therapy. The…

This study is testing whether adding the drug fruquintinib to standard chemotherapy (FOLFIRI) can better control advanced colorectal cancer that has spread. The trial is for people whose cancer has continued to grow despite initial treatment. Researchers will measure how long the…

This study is testing whether a new two-drug immunotherapy combination (BMS-986489) works better than the current standard immunotherapy (durvalumab) for people with limited-stage small cell lung cancer. About 250 participants who have already completed initial chemotherapy and r…

This study is testing if two already-approved drugs for multiple myeloma, teclistamab and talquetamab, can be safely given to patients at home instead of in the hospital. Researchers will give patients preventive medications before treatment to try to reduce common and serious si…

This study is testing if a new drug combination that activates the immune system can work as well as or better than a stem cell transplant for people newly diagnosed with multiple myeloma. About 100 participants will be randomly assigned to receive either the new drug therapy or …